
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4765028/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, The, 1997, 350, 757-764.	13.7	2,841
2	Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, The, 2000, 356, 366-372.	13.7	1,156
3	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension, 2013, 31, 1731-1768.	0.5	1,124
4	Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension. New England Journal of Medicine, 2003, 348, 2407-2415.	27.0	997
5	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension, 2014, 32, 1359-1366.	0.5	758
6	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. Journal of Hypertension, 2008, 26, 1505-1526.	0.5	707
7	Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension. Journal of the American College of Cardiology, 2011, 58, 765-773.	2.8	538
8	Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis. Vascular Health and Risk Management, 2009, 5, 185.	2.3	376
9	Diagnostic Tests for Renal Artery Stenosis in Patients Suspected of Having Renovascular Hypertension. Annals of Internal Medicine, 2001, 135, 401.	3.9	336
10	Novel Baroreflex Activation Therapy in Resistant Hypertension. Journal of the American College of Cardiology, 2010, 56, 1254-1258.	2.8	321
11	Accuracy of Computed Tomographic Angiography and Magnetic Resonance Angiography for Diagnosing Renal Artery Stenosis. Annals of Internal Medicine, 2004, 141, 674.	3.9	313
12	Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. Journal of Hypertension, 2003, 21, 2251-2257.	0.5	305
13	Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension. Circulation, 2000, 102, 1139-1144.	1.6	271
14	Predictive Value of Clinic and Ambulatory Heart Rate for Mortality in Elderly Subjects With Systolic Hypertension. Archives of Internal Medicine, 2002, 162, 2313.	3.8	254
15	Increased Aortic Pulse Wave Velocity Is Associated With Silent Cerebral Small-Vessel Disease in Hypertensive Patients. Hypertension, 2008, 52, 1120-1126.	2.7	251
16	First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vascular Medicine, 2019, 24, 164-189.	1.5	232
17	The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. Journal of Hypertension, 2002, 20, 2023-2027.	0.5	221
18	Home Blood Pressure Measurement. Journal of the American College of Cardiology, 2005, 46, 743-751.	2.8	183

#	Article	IF	CITATIONS
19	Vascular inflammation in cerebral small vessel disease. Neurobiology of Aging, 2012, 33, 1800-1806.	3.1	175
20	Prognostic Significance of Renal Function in Elderly Patients with Isolated Systolic Hypertension. Journal of the American Society of Nephrology: JASN, 2002, 13, 2213-2222.	6.1	172
21	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. Journal of Hypertension, 2004, 22, 847-857.	0.5	172
22	Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors. New England Journal of Medicine, 2016, 374, 384-386.	27.0	170
23	Self-Measurement of Blood Pressure at Home Reduces the Need for Antihypertensive Drugs. Hypertension, 2007, 50, 1019-1025.	2.7	164
24	Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patients. Frontiers in Aging Neuroscience, 2013, 5, 72.	3.4	159
25	Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients With Drug-Resistant Arterial Hypertension. Hypertension, 2009, 54, 530-536.	2.7	156
26	Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension, 2003, 41, 431-436.	2.7	154
27	European consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2014, 32, 1367-1378.	0.5	154
28	Renal Clearance of B-Type Natriuretic Peptide and Amino Terminal Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 2009, 53, 884-890.	2.8	142
29	Sharing Clinical Trial Data. JAMA - Journal of the American Medical Association, 2016, 315, 467.	7.4	141
30	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.7	133
31	Prevalence, Causes, and Consequences of Masked Hypertension: A Meta-analysis. American Journal of Hypertension, 2008, 21, 969-975.	2.0	128
32	On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension. Archives of Internal Medicine, 2007, 167, 1884.	3.8	124
33	Renal Hemodynamics and the Renin–Angiotensin–Aldosterone System in Normotensive Subjects with Hypertensive and Normotensive Parents. New England Journal of Medicine, 1991, 324, 1305-1311.	27.0	117
34	Genetic predisposition to salt-sensitivity. Journal of Hypertension, 2004, 22, 1243-1249.	0.5	116
35	Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Journal of Hypertension, 2001, 19, 511-519.	0.5	113
36	Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood, 2010, 115, 5121-5123.	1.4	113

#	Article	IF	CITATIONS
37	Is There a Side Predilection for Cerebrovascular Disease?. Hypertension, 2003, 42, 56-60.	2.7	109
38	Thin GBM nephropathy: Premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney International, 1997, 51, 1596-1601.	5.2	108
39	Treatment of Hypertension in the Oldest Old. Hypertension, 2014, 63, 433-441.	2.7	105
40	The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology, 2017, 32, 197-209.	3.1	103
41	Dementia risk in renal dysfunction. Neurology, 2017, 88, 198-208.	1.1	103
42	Angiotensin II Sensitivity Is Associated With the Angiotensin II Type 1 Receptor A1166C Polymorphism in Essential Hypertensives on a High Sodium Diet. Hypertension, 2000, 36, 411-416.	2.7	100
43	Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment. Hypertension, 2011, 58, 573-578.	2.7	100
44	Influence of Diabetes and Type of Hypertension on Response to Antihypertensive Treatment. Hypertension, 2000, 35, 1038-1042.	2.7	98
45	Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy. Hypertension, 2017, 69, 836-843.	2.7	96
46	Clinical Significance of Renal Function in Hypertensive Patients at High Risk. Archives of Internal Medicine, 2004, 164, 2459.	3.8	95
47	Brain Microbleeds Are Associated With Ambulatory Blood Pressure Levels in a Hypertensive Population. Hypertension, 2008, 51, 62-68.	2.7	94
48	Ambulatory pulse pressure aspredictor of outcome in older patients with systolic hypertension. American Journal of Hypertension, 2002, 15, 835-843.	2.0	93
49	Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension, 2005, 23, 2063-2070.	0.5	89
50	Uniform Format for Disclosure of Competing Interests in ICMJE Journals. New England Journal of Medicine, 2009, 361, 1896-1897.	27.0	89
51	The Prothrombotic Paradox of Hypertension. Hypertension, 2005, 46, 1236-1242.	2.7	80
52	First international consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2019, 37, 229-252.	0.5	80
53	Improved Cardiac Structure and Function With Chronic Treatment Using an Implantable Device in Resistant Hypertension. Journal of the American College of Cardiology, 2011, 57, 1787-1788.	2.8	77
54	Toward More Uniform Conflict Disclosures — The Updated ICMJE Conflict of Interest Reporting Form. New England Journal of Medicine, 2010, 363, 188-189.	27.0	76

#	Article	IF	CITATIONS
55	Nonsteroidal Anti-Inflammatory Drugs and Hypertension. Drugs, 1996, 51, 179-187.	10.9	74
56	The Framingham prediction rule is not valid in a European population of treated hypertensive patients. Journal of Hypertension, 2002, 20, 1973-1980.	0.5	74
57	Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundamental and Clinical Pharmacology, 2005, 19, 411-419.	1.9	71
58	Total Cerebral Small Vessel Disease MRI Score Is Associated with Cognitive Decline in Executive Function in Patients with Hypertension. Frontiers in Aging Neuroscience, 2016, 8, 301.	3.4	71
59	Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. Journal of Hypertension, 1999, 17, 873-881.	0.5	68
60	Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion, 2012, 52, 470-477.	1.6	67
61	Calcium Channel Blockade and Cardiovascular Prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension, 1998, 32, 410-416.	2.7	66
62	The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. Journal of Hypertension, 2006, 24, 1541-1548.	0.5	66
63	Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension, 1991, 9, 225-230.	0.5	65
64	Can the blood pressure predict cognitive task performance in a healthy population sample?. Journal of Hypertension, 1997, 15, 1069-1076.	0.5	65
65	Prognostic Significance of Electrocardiographic Voltages and Their Serial Changes in Elderly With Systolic Hypertension. Hypertension, 2004, 44, 459-464.	2.7	64
66	Polymorphisms in human connexin40 gene promoter are associated with increased risk of hypertension in men. Journal of Hypertension, 2006, 24, 325-330.	0.5	64
67	Basal Ganglia Enlarged Perivascular Spaces are Linked to Cognitive Function in Patients with Cerebral Small Vessel Disease. Current Neurovascular Research, 2014, 11, 136-141.	1.1	63
68	Different classifications of nocturnal blood pressure dipping affect the prevalence of dippers and nondippers and the relation with target-organ damage. Journal of Hypertension, 2008, 26, 691-698.	0.5	61
69	Bilateral or Unilateral Stimulation for Baroreflex Activation Therapy. Hypertension, 2015, 65, 187-192.	2.7	60
70	Assessing Medication Adherence Simultaneously by Electronic Monitoring and Pill Count in Patients With Mild-to-Moderate Hypertension. American Journal of Hypertension, 2010, 23, 149-154.	2.0	59
71	The Impact of Differences in EQ-5D and SF-6D Utility Scores on the Acceptability of Cost–Utility Ratios: Results across Five Trial-Based Cost–Utility Studies. Value in Health, 2010, 13, 222-229.	0.3	58
72	Associations of the Angiotensin II Type 1 Receptor A <sup>1166</sup> C and the Endothelial NO Synthase G <sup>894</sup> T Gene Polymorphisms With Silent Subcortical White Matter Lesions in Essential Hypertension. Stroke, 2005, 36, 1869-1873.	2.0	57

PETER W DE LEEUW

#	Article	IF	CITATIONS
73	Short-term and long-term repeatability of the morning blood pressure in older patients with isolated systolic hypertension. Journal of Hypertension, 2008, 26, 1328-1335.	0.5	57
74	Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjects. American Journal of Clinical Nutrition, 2008, 88, 1697-1702.	4.7	56
75	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.5	56
76	Calcium scores and matrix Gla protein levels: association with vitamin K status. European Journal of Clinical Investigation, 2010, 40, 344-349.	3.4	55
77	Preeclampsia and maladaptation to pregnancy: A role for atrial natriuretic peptide?. Kidney International, 2001, 60, 1397-1406.	5.2	53
78	Electronic Monitoring of Adherence as a Tool to Improve Blood Pressure ControlA Randomized Controlled Trial. American Journal of Hypertension, 2007, 20, 119-125.	2.0	53
79	Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial). Nutrients, 2015, 7, 8905-8915.	4.1	52
80	Angiogenic T-Cells and Putative Endothelial Progenitor Cells in Hypertension-Related Cerebral Small Vessel Disease. Stroke, 2012, 43, 256-258.	2.0	50
81	Subjective Cognitive Failures in Patients With Hypertension Are Related to Cognitive Performance and Cerebral Microbleeds. Hypertension, 2014, 64, 653-657.	2.7	49
82	Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Pressure Monitoring, 2008, 13, 352-365.	0.8	48
83	Influence of Interdialytic Weight Gain on Blood Pressure in Hemodialysis Patients. Blood Purification, 1994, 12, 259-266.	1.8	47
84	Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients. Journal of Hypertension, 2009, 27, 846-853.	0.5	47
85	Associations of ambulatory blood pressure levels with white matter hyperintensity volumes in hypertensive patients. Journal of Hypertension, 2009, 27, 1446-1452.	0.5	47
86	Novel procedure- and device-based strategies in the management of systemic hypertension. European Heart Journal, 2011, 32, 537-544.	2.2	47
87	Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population. Journal of Hypertension, 2003, 21, 81-86.	0.5	46
88	Is a high serum cholesterol level associated with longer survival in elderly hypertensives?. Journal of Hypertension, 1990, 8, 755-761.	0.5	45
89	Doseâ€dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects. Blood Pressure, 2009, 18, 44-50.	1.5	44
90	Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. Journal of Hypertension, 2002, 20, 493-499.	0.5	43

#	Article	IF	CITATIONS
91	Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H1206-H1212.	3.2	40
92	Prevalence of the white-coat effect at multiple visits before and during treatment. Journal of Hypertension, 2006, 24, 2357-2363.	0.5	40
93	Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. Journal of the American College of Cardiology, 1994, 23, 82-91.	2.8	39
94	Quantitative analysis of retinal vascular changes in essential and renovascular hypertension. Journal of Hypertension, 1995, 13, 1729???1733.	0.5	39
95	A prospective study of the natural history of idiopathic non-proteinuric hematuria. Kidney International, 1996, 49, 222-225.	5.2	39
96	Microvascular Abnormalities in Chronic Heart Failure: A Cross-Sectional Analysis. Microcirculation, 2003, 10, 471-478.	1.8	39
97	Neural activity of the cardiac baroreflex decreases with age in normotensive and hypertensive subjects. Journal of Hypertension, 2005, 23, 815-823.	0.5	39
98	Carotid Baroreflex Activation: Past, Present, and Future. Current Hypertension Reports, 2010, 12, 61-66.	3.5	38
99	Toward More Uniform Conflict Disclosures. JAMA - Journal of the American Medical Association, 2010, 304, 212.	7.4	38
100	Renal function in the elderly: Results from the European Working Party on High Blood Pressure in the Elderly trial. American Journal of Medicine, 1991, 90, S45-S49.	1.5	37
101	Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials, 2011, 12, 13.	1.6	37
102	Masked hypertension, a review of the literature. Blood Pressure Monitoring, 2007, 12, 267-273.	0.8	36
103	Renal Responses to Long-Term Carotid Baroreflex Activation Therapy in Patients With Drug-Resistant Hypertension. Hypertension, 2013, 61, 1334-1339.	2.7	36
104	Reduced Uteroplacental Blood Flow Alters Renal Arterial Reactivity and Glomerular Properties in the Rat Offspring. Hypertension, 2004, 43, 1283-1289.	2.7	34
105	Birth Weight and Creatinine Clearance in Young Adult Twins. Journal of the American Society of Nephrology: JASN, 2005, 16, 2471-2476.	6.1	34
106	A Subnormal Plasma Volume in Formerly Preeclamptic Women is Associated with a Low Venous Capacitance. Journal of the Society for Gynecologic Investigation, 2005, 12, 107-111.	1.7	34
107	A Low Plasma Volume in Formerly Preeclamptic Women Predisposes to the Recurrence of Hypertensive Complications in the Next Pregnancy. Journal of the Society for Gynecologic Investigation, 2006, 13, 598-603.	1.7	34
108	Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses. Vascular Health and Risk Management, 2008, Volume 4, 427-436.	2.3	34

#	Article	IF	CITATIONS
109	Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. Journal of Hypertension, 2010, 28, 622-627.	0.5	34
110	MRI progression of cerebral small vessel disease and cognitive decline in patients with hypertension. Journal of Hypertension, 2017, 35, 1263-1270.	0.5	34
111	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
112	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	3.8	33
113	Is a Series of Blood Pressure Measurements by the General Practitioner or the Patient a Reliable Alternative to Ambulatory Blood Pressure Measurement? A Study in General Practice With Reference to Short-term and Long-term Between-Visit Variability. American Journal of Hypertension, 1997, 10, 879-885.	2.0	32
114	Blood pressure measurement in research. Blood Pressure Monitoring, 2002, 7, 83-87.	0.8	32
115	α-Adducin Cly460Trp Polymorphism and Renal Hemodynamics in Essential Hypertension. Hypertension, 2004, 44, 419-423.	2.7	32
116	Rheos®Baroreflex Hypertension Therapy™ System to treat resistant hypertension. Expert Review of Medical Devices, 2008, 5, 33-39.	2.8	32
117	Protein supplementation lowers blood pressure in overweight adults: effect of dietary proteins on blood pressure (PROPRES), a randomized trial. American Journal of Clinical Nutrition, 2012, 95, 966-971.	4.7	31
118	Comparison of different fixed antihypertensive combination drugs. Journal of Hypertension, 1997, 15, 87-91.	0.5	30
119	Persistent abnormalities in plasma volume and renal hemodynamics in patients with a history of preeclampsia. American Journal of Obstetrics and Gynecology, 1998, 179, 690-696.	1.3	30
120	Asymmetry of Renal Blood Flow in Patients With Moderate to Severe Hypertension. Hypertension, 2003, 41, 108-113.	2.7	30
121	Angiotensin-(1–7)–Induced Renal Vasodilation in Hypertensive Humans Is Attenuated by Low Sodium Intake and Angiotensin II Co-Infusion. Hypertension, 2013, 62, 789-793.	2.7	30
122	Enrichment of Rare Variants in Loeys–Dietz Syndrome Genes in Spontaneous Coronary Artery Dissection but Not in Severe Fibromuscular Dysplasia. Circulation, 2020, 142, 1021-1024.	1.6	30
123	The anabolic role of the Warburg, Cori-cycle and Crabtree effects in health and disease. Clinical Nutrition, 2021, 40, 2988-2998.	5.0	30
124	Configuration of the microcirculation in pre-eclampsia: possible role of the venular system. Journal of Hypertension, 2007, 25, 1665-1670.	0.5	29
125	Interaction between the Gly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 2009, 27, 61-68.	0.5	29
126	The M235T Polymorphism in the AGT Gene and CHD Risk: Evidence of a Hardy-Weinberg Equilibrium Violation and Publication Bias in a Meta-Analysis. PLoS ONE, 2008, 3, e2533.	2.5	29

#	Article	IF	CITATIONS
127	Autoantibodies Against Oxidized Low-Density Lipoprotein in Cerebral Small Vessel Disease. Stroke, 2010, 41, 2687-2689.	2.0	28
128	Obesity is associated with impaired endothelial function in the postprandial state. Microvascular Research, 2011, 82, 423-429.	2.5	28
129	Determining the feasibility of objective adherence measurement with blister packaging smart technology. American Journal of Health-System Pharmacy, 2012, 69, 872-879.	1.0	28
130	Arterial stiffness and decline of renal function in a primary care population. Hypertension Research, 2017, 40, 73-78.	2.7	28
131	Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction?. Journal of Hypertension, 1998, 16, 1425-1432.	0.5	27
132	Interpretation of renal angiography by radiologists. Journal of Hypertension, 1999, 17, 1737-1741.	0.5	27
133	Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients. Pharmacoeconomics, 2007, 25, 239-251.	3.3	27
134	Atherosclerotic Renal Artery Stenosis and Hypertension: Pragmatism, Pitfalls, and Perspectives. American Journal of Medicine, 2016, 129, 635.e5-635.e14.	1.5	27
135	Differential tissue expression of Annexin VIII in human. FEBS Letters, 1994, 349, 120-124.	2.8	26
136	Variation in Renin-Angiotensin System and Salt-Sensitivity Genes and the Risk of Diabetes Mellitus Associated With the Use of Thiazide Diuretics. American Journal of Hypertension, 2009, 22, 545-551.	2.0	26
137	Meal-Related Increases in Microvascular Vasomotion Are Impaired in Obese Individuals. Diabetes Care, 2011, 34, S342-S348.	8.6	26
138	Electronic Monitoring of Adherence, Treatment of Hypertension, and Blood Pressure Control. American Journal of Hypertension, 2012, 25, 54-59.	2.0	26
139	Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Lancet, The, 2016, 387, e9-e11.	13.7	26
140	Pharmacological and Nutritional Modulation of Vascular Calcification. Nutrients, 2020, 12, 100.	4.1	26
141	Hemodynamic, Neurohumoral, and Myocardial Energetic Effects of Pimobendan, a Novel Calcium-Sensitizing Compound, in Patients with Mild to Moderate Heart Failure. Journal of Cardiovascular Pharmacology, 1994, 24, 730-739.	1.9	25
142	Endothelial Activation Is Associated With Cognitive Performance in Patients With Hypertension. American Journal of Hypertension, 2016, 29, 464-469.	2.0	25
143	Vascular distensibility and compliance in salt-sensitive and salt-resistant borderline hypertension. Journal of Hypertension, 1993, 11, 1199???1208.	0.5	24
144	Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. Journal of Hypertension, 2005, 23, 753-758.	0.5	23

#	Article	IF	CITATIONS
145	α-Adducin <i>Gly</i> 460 <i>Trp</i> Variant Increases the Risk of Stroke in Hypertensive Dutch Women. Hypertension, 2008, 51, 1665-1670.	2.7	23
146	The M235T Variant of the Angiotensinogen Gene Is Related to Development of Self-Reported Hypertension during Pregnancy: The Prospect-EPIC Cohort Study. Hypertension Research, 2008, 31, 1299-1305.	2.7	23
147	Predictors of clinical outcome after stent placement in atherosclerotic renal artery stenosis: a systematic review and meta-analysis of prospective studies. Journal of Hypertension, 2010, 28, 2370-2377.	0.5	23
148	Angiotensin II Enhances Insulin-Stimulated Whole-Body Glucose Disposal but Impairs Insulin-Induced Capillary Recruitment in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3901-3908.	3.6	23
149	Accuracy of oscillometric blood pressure monitors for the detection of atrial fibrillation: a systematic review. Expert Review of Medical Devices, 2012, 9, 635-640.	2.8	23
150	An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. Journal of the American Society of Hypertension, 2017, 11, 81-91.	2.3	23
151	Framingham Stroke Risk Profile is related to cerebral small vessel disease progression and lower cognitive performance in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 240-245.	2.0	23
152	Association between the α-adducin Gly460Trp polymorphism and systolic blood pressure in familial combined hyperlipidemia. American Journal of Hypertension, 2001, 14, 1185-1190.	2.0	22
153	Phase-Contrast Magnetic Resonance Flow Quantification in Renal Arteries. Hypertension, 2003, 41, 114-118.	2.7	22
154	Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension. Journal of Hypertension, 2004, 22, 81-87.	0.5	21
155	Baroreflex Activation Therapy for the Treatment of Drug-Resistant Hypertension: New Developments. Cardiology Research and Practice, 2012, 2012, 1-7.	1.1	21
156	Obtaining the family history for common, multifactorial diseases by family physicians. A descriptive systematic review. European Journal of General Practice, 2009, 15, 231-242.	2.0	20
157	Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. American Journal of Physiology - Renal Physiology, 2012, 303, F149-F156.	2.7	20
158	Sustained acute voltage-dependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. Journal of Hypertension, 2012, 30, 1665-1670.	0.5	20
159	Atherosclerotic Renal Artery Stenosis: Should we Intervene Earlier?. Current Hypertension Reports, 2018, 20, 35.	3.5	20
160	Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. American Journal of Cardiology, 1991, 68, 181-186.	1.6	19
161	Colonization with Pseudomonas aeruginosa in Patients Developing Ventilator-Associated Pneumonia. Infection Control and Hospital Epidemiology, 1998, 19, 853-855.	1.8	19
162	Renal Artery Stenosis: Cost-effectiveness of Diagnosis and Treatment. Radiology, 2007, 244, 505-513.	7.3	19

#	Article	IF	CITATIONS
163	Treatment of Atherosclerotic Renal Artery Stenosis. JAMA - Journal of the American Medical Association, 2013, 309, 663.	7.4	19
164	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. Journal of Hypertension, 2018, 36, 451-461.	0.5	19
165	Venous carbon dioxide embolism during laparoscopic cholecystectomy a literature review. European Journal of Internal Medicine, 2019, 60, 9-12.	2.2	19
166	A new simplified model for predicting 30-day mortality in older medical emergency department patients: The rise up score. European Journal of Internal Medicine, 2020, 77, 36-43.	2.2	19
167	Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovascular Drugs and Therapy, 2000, 14, 49-53.	2.6	18
168	Baroreflex Activation Therapy Lowers Arterial Pressure Without Apparent Stimulation of the Carotid Bodies. Hypertension, 2015, 65, 1217-1222.	2.7	18
169	Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet. Cardiovascular Research, 1998, 39, 442-450.	3.8	17
170	Validation of a prediction rule for renal artery stenosis. Journal of Hypertension, 2005, 23, 1583-1588.	0.5	17
171	OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics, 2005, 6, 755-775.	1.3	17
172	Formerly Preeclamptic Women With a Subnormal Plasma Volume Are Unable to Maintain a Rise in Stroke Volume During Moderate Exercise. Journal of the Society for Gynecologic Investigation, 2005, 12, 599-603.	1.7	17
173	Prevalence and Persistence of Masked Hypertension in Treated Hypertensive Patients. American Journal of Hypertension, 2007, 20, 1258-1265.	2.0	17
174	Renal Handling of Matrix Gla-Protein in Humans with Moderate to Severe Hypertension. Hypertension Research, 2008, 31, 1745-1751.	2.7	17
175	Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. International Journal of Clinical Pharmacy, 2009, 31, 158-164.	1.4	17
176	CD4+CD28null T Cells are related to previous cytomegalovirus infection but not to accelerated atherosclerosis in ANCA-associated vasculitis. Rheumatology International, 2017, 37, 791-798.	3.0	17
177	Angiotensin II Sensitivity in Nonpregnant Formerly Preeclamptic Women and Halthy Parous Contorls. Journal of the Society for Gynecologic Investigation, 2004, 11, 416-422.	1.7	16
178	Mechanisms of adenosine-induced renal vasodilatation in hypertensive patients. Journal of Hypertension, 2005, 23, 1731-1736.	0.5	16
179	Subjective sleep disturbance increases the nocturnal blood pressure level and attenuates the correlation with target-organ damage. Journal of Hypertension, 2011, 29, 242-250.	0.5	16
180	Differential effects of proteins and carbohydrates on postprandial blood pressure-related responses. British Journal of Nutrition, 2014, 112, 600-608.	2.3	16

#	Article	IF	CITATIONS
181	Intact and C-Terminal FCF23 Assays—Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4875-e4885.	3.6	16
182	Angiotensin-(1-7) as a strategy in the treatment of hypertension?. Current Opinion in Nephrology and Hypertension, 2014, 23, 480-486.	2.0	15
183	Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. European Journal of Human Genetics, 2015, 23, 381-387.	2.8	15
184	Diuretics ??? a risk in the long-term treatment of hypertensive patients?. Journal of Hypertension, 1988, 6, 925-930.	0.5	14
185	The Effects of Calcium Channel Blockers on Cardiovascular Outcomes: a Review of Randomised Controlled Trials. Blood Pressure, 2002, 11, 71-78.	1.5	14
186	Effects of nifedipine GITS and diuretics in isolated systolic hypertension - a subanalysis of the INSIGHT study. Blood Pressure, 2004, 13, 310-315.	1.5	14
187	Masked Hypertension and White-Coat Hypertension Prognosis. Journal of the American College of Cardiology, 2006, 47, 2127.	2.8	14
188	Acute angiotensin II receptor blockade improves insulin-induced microvascular function in hypertensive individuals. Microvascular Research, 2011, 82, 77-83.	2.5	14
189	Angiotensin-(1-7)-induced renal vasodilation is reduced in human kidneys with renal artery stenosis. Journal of Hypertension, 2014, 32, 2428-2432.	0.5	14
190	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	3.8	14
191	Progression of Brain Microbleeds in Essential Hypertensive Patients: A 2-Year Follow-up Study. American Journal of Hypertension, 2014, 27, 1045-1051.	2.0	13
192	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. Journal of Hypertension, 2018, 36, 462-471.	0.5	13
193	The effect of medication on the aldosteroneâ€ŧoâ€renin ratio. A critical review of the literature. Journal of Clinical Hypertension, 2021, 23, 208-214.	2.0	13
194	Renal vascular tachyphylaxis to angiotensin II: Specificity of the response for angiotensin. Life Sciences, 1982, 30, 813-819.	4.3	12
195	Selective Enhancement of α2-Adrenoceptor-Mediated Vasoconstriction in Insulin-Dependent Diabetic Patients with Microalbuminuria. Clinical Science, 1995, 88, 421-426.	4.3	12
196	Trough-To-Peak Versus Surface Ratio in the Assessment of Antihypertensive Agents. Blood Pressure, 1995, 4, 350-357.	1.5	12
197	A novel approach to the study of human microcirculation: reactivity to locally applied angiotensin II in the conjunctival microvascular bed. Journal of Hypertension, 2006, 24, 2225-2230.	0.5	12
198	Renal hemodynamics and renin–angiotensin system activity in humans with multifocal renal artery fibromuscular dysplasia. Journal of Hypertension, 2016, 34, 1160-1169.	0.5	12

#	Article	IF	CITATIONS
199	Pathophysiological differences between multifocal fibromuscular dysplasia and atherosclerotic renal artery stenosis. Journal of Hypertension, 2017, 35, 845-852.	0.5	12
200	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	0.5	12
201	Renal artery fibromuscular dysplasia and its effect on the kidney. Hypertension Research, 2018, 41, 639-648.	2.7	12
202	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
203	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. American Heart Journal, 2020, 226, 60-68.	2.7	12
204	Hypertension and the Development of Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S9-S15.	1.9	12
205	Glucocorticoids affect metabolic but not muscle microvascular insulin sensitivity following high versus low salt intake. JCI Insight, 2020, 5, .	5.0	12
206	Short- and long-term effects of ramipril in hypertension. American Journal of Cardiology, 1987, 59, D79-D82.	1.6	11
207	Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics, 2008, 18, 631-636.	1.5	11
208	Improved Functional Capacity and Cardiovascular Structure after Baroreflex Activation Therapyâ,,¢ in Resistant Hypertension Patients with Symptomatic Heart Failure: Results from European and United States Trials of the Rheos® System. Journal of Cardiac Failure, 2009, 15, S63.	1.7	11
209	Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial. Journal of Hypertension, 2010, 28, 865-874.	0.5	11
210	Salt and Sensitivity. Hypertension, 2013, 62, 461-462.	2.7	11
211	Coronary Tortuosity: A Clue to the Diagnosis of Fibromuscular Dysplasia?. American Journal of Hypertension, 2017, 30, 776-780.	2.0	11
212	Chlamydia pneumoniae Seropositivity and Systemic and Renovascular Atherosclerotic Disease. Archives of Internal Medicine, 2002, 162, 786.	3.8	10
213	Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives?. Hypertension, 2003, 41, 119-123.	2.7	10
214	Genetic Risk of Atherosclerotic Renal Artery Disease. Hypertension, 2004, 44, 448-453.	2.7	10
215	Improved Cardiac Structure and Function in Early-Stage Heart Failure with Chronic Treatment Using an Implantable Device: Results from European and United States Trials of the Rheos® System. Journal of Cardiac Failure, 2008, 14, S48.	1.7	10
216	Combination perindopril/indapamide for the treatment of hypertension: A review. Expert Opinion on Pharmacotherapy, 2011, 12, 1827-1833.	1.8	10

#	Article	IF	CITATIONS
217	Blood Pressure Decreases More after High-Carbohydrate Meals Than after High-Protein Meals in Overweight Adults with Elevated Blood Pressure, but There Is No Difference after 4 Weeks of Consuming a Carbohydrate-Rich or Protein-Rich Diet. Journal of Nutrition, 2013, 143, 424-429.	2.9	10
218	Blood pressure and renal function before and after percutaneous transluminal renal angioplasty in fibromuscular dysplasia. Journal of Hypertension, 2013, 31, 1183-1188.	0.5	10
219	Effect of increased protein intake on renal acid load and renal hemodynamic responses. Physiological Reports, 2016, 4, e12687.	1.7	10
220	Pregnancy-Related Complications in Patients With Fibromuscular Dysplasia. Hypertension, 2020, 76, 545-553.	2.7	10
221	Sensitivity of Blood Pressure and Renin Activation During Sodium Restriction. Hypertension, 1997, 30, 1216-1222.	2.7	10
222	Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. Journal of Hypertension, 2002, 20, 2275-2283.	0.5	9
223	Effect of glycyrrhetinic acid on 11Î <sup>2</sup> -hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clinical Science, 2002, 102, 203.	4.3	9
224	Microvascular adaptation to changes in dietary sodium is disturbed in patients with essential hypertension. Journal of Hypertension, 2005, 23, 127-132.	0.5	9
225	Uniform format for disclosure of competing interests in ICMJE journals. Cmaj, 2009, 181, 565-565.	2.0	9
226	Reasons for nonâ€response in observational pharmacogenetic research. Pharmacoepidemiology and Drug Safety, 2009, 18, 665-671.	1.9	9
227	The association between arterial stiffness and the angiotensin II type 1 receptor (A1166C) polymorphism is influenced by the use of cardiovascular medication. Journal of Hypertension, 2009, 27, 69-75.	0.5	9
228	Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients. Current Neurovascular Research, 2010, 7, 1-5.	1.1	9
229	Dietary proteins improve endothelial function under fasting conditions but not in the postprandial state, with no effects on markers of low-grade inflammation. British Journal of Nutrition, 2015, 114, 1819-1828.	2.3	9
230	Age-related effects of placebo and active treatment in patients beyond the age of 60 years: the need for a proper control group. Journal of Hypertension, 1990, 8, 997-1002.	0.5	8
231	Acetylcholine-induced vasodilatation in the human hypertensive kidney. Journal of Hypertension, 1997, 15, 1649-1651.	0.5	8
232	How do angiotensin II receptor antagonists affect blood pressure?. American Journal of Cardiology, 1999, 84, 5-6.	1.6	8
233	Genetic influences on 24???h blood pressure profiles in a hypertensive population: role of the angiotensin-converting enzyme insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphisms. Blood Pressure Monitoring, 2005, 10, 135-141.	0.8	8
234	Pre-pregnant Prediction of Recurrent Preeclampsia in Normotensive Thrombophilic Formerly Preeclamptic Women Receiving Prophylactic Antithrombotic Medication. Journal of the Society for Gynecologic Investigation, 2005, 12, 112-117.	1.7	8

#	Article	IF	CITATIONS
235	Renal Contribution to Increased Clearance of Exogenous Growth Hormone in Obese Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 795-799.	3.6	8
236	Renin-Angiotensin System and Nitric Oxide Synthase Gene Polymorphisms in Relation to Stroke. American Journal of Hypertension, 2007, 20, 764-770.	2.0	8
237	Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 101-108.	1.7	8
238	Genetic variation in the renin—angiotensin system, use of renin—angiotensin system inhibitors and the risk of myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 208-214.	1.7	8
239	Differences in renal hemodynamics and renin secretion between patients with unifocal and multifocal fibromuscular dysplasia. Journal of Hypertension, 2018, 36, 1729-1735.	0.5	8
240	Validating the RISE UP score for predicting prognosis in patients with COVID-19 in the emergency department: a retrospective study. BMJ Open, 2021, 11, e045141.	1.9	8
241	Dissociation between the renal effects of angiotensin I and II in sodium-restricted normal subjects. Cardiovascular Research, 1998, 38, 215-220.	3.8	7
242	The elderly hypertensive; cardiovascular and neurohormonal profile. Cardiovascular Drugs and Therapy, 2001, 15, 263-267.	2.6	7
243	The Contribution of Risk Factors to Blood Pressure Heritability Estimates in Young Adults: The East Flanders Prospective Twin Study. Twin Research and Human Genetics, 2004, 7, 245-253.	1.0	7
244	Baroreflex activation therapy for patients with drug-resistant hypertension. Expert Review of Cardiovascular Therapy, 2014, 12, 955-962.	1.5	7
245	Study protocol for a multicentre prospective cohort study to identify predictors of adverse outcome in older medical emergency department patients (the Risk Stratification in the Emergency Department) Tj ETQq1	1 <b>£177</b> 8431	47rgBT /Ove
246	Index for Normalization of Blood Volume. Clinical Science, 1982, 63, 375s-377s.	0.0	6
247	Stimulation of renin by blockade of α2-adrenoceptors in man. Journal of Hypertension, 1988, 6, S416-417.	0.5	6
248	On the significance of renal vein renins in renovascular hypertension. Journal of Hypertension, 2002, 20, 843-845.	0.5	6
249	Disclosure of competing interests. BMJ: British Medical Journal, 2009, 339, b4144-b4144.	2.3	6
250	Hypertensive organ damage predicts future cognitive performance: A 9â€year followâ€up study in patients with hypertension. Journal of Clinical Hypertension, 2018, 20, 1458-1463.	2.0	6
251	Confounders of the aldosteroneâ€toâ€renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. Journal of Clinical Hypertension, 2021, 23, 201-207.	2.0	6
252	Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study. BMC Geriatrics, 2022, 22, 36.	2.7	6

PETER W DE LEEUW

#	Article	IF	CITATIONS
253	Natriuretic effect of nitrendipine is preceded by transient systemic and renal hemodynamic effects. Cardiovascular Drugs and Therapy, 1997, 11, 33-38.	2.6	5
254	Tomato Extract for Hypertension?. Cardiovascular Drugs and Therapy, 2009, 23, 107-108.	2.6	5
255	The New ICMJE Recommendations. Indian Journal of Medical Microbiology, 2014, 32, 219-220.	0.8	5
256	Baropacing as a new option for treatment of resistant hypertension. European Journal of Pharmacology, 2015, 763, 23-27.	3.5	5
257	Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Annals of Internal Medicine, 2013, 158, JC7.	3.9	5
258	Alpha-adrenoceptors and the kidney. Journal of Hypertension, 1988, 6, S21???24.	0.5	4
259	Trandolapril: A Clinical Profile. American Journal of Hypertension, 1995, 8, 68S-70S.	2.0	4
260	Drug-Induced Hypertension. Drugs and Aging, 1997, 11, 178-185.	2.7	4
261	Cost analysis of procedures related to the management of renal artery stenosis from various perspectives. European Radiology, 2006, 16, 154-160.	4.5	4
262	Sex-specific effect of the α-adducin (G460W) and AGTR1 (A1166C) polymorphism on carotid intima–media thickness. Journal of Hypertension, 2009, 27, 2165-2173.	0.5	4
263	Nailfold capillary density in salt-sensitive and salt-resistant borderline hypertension. Journal of Hypertension, 1993, 11, 1195???1198.	0.5	3
264	Vascular compliance in sodium-sensitive and sodium-resistant borderline hypertensive patients. Kidney International, 1995, 47, 169-176.	5.2	3
265	Toward more uniform conflict disclosures: updated ICMJE conflict of interest reporting form. Cmaj, 2010, 182, E425-E425.	2.0	3
266	Dual renin-angiotensin system blockade. BMJ: British Medical Journal, 2012, 344, e656-e656.	2.3	3
267	Sodium Intake as a Modulator of Kidney Function. Current Hypertension Reviews, 2015, 11, 57-60.	0.9	3
268	Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. Cmaj, 2016, 188, 91-92.	2.0	3
269	The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients. Hypertension Research, 2017, 40, 568-572.	2.7	3
270	Drug-Resistant Hypertension. Hypertension, 2019, 73, 920-925.	2.7	3

#	Article	IF	CITATIONS
271	Toward More Uniform Conflict Disclosures - The Updated ICMJE Reporting Form for Disclosure of Potential Conflicts of Interest. Revista Medica De Chile, 2010, 138, .	0.2	3
272	Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans. Journal of Bone and Mineral Research, 2020, 37, 1170-1178.	2.8	3
273	Acute responses to urapidil in hypertensive persons. American Journal of Cardiology, 1989, 64, D22-D24.	1.6	2
274	Comparison of a vasodilating beta-blocker and a cardioselective beta-blocker in long-term treatment of hypertension: a European multicentre study. Journal of Hypertension, 1989, 7, S266-267.	0.5	2
275	Doxazosin versus nitrendipine: A double-blind comparative study in patients adhering to a sodium-restricted diet. Cardiovascular Drugs and Therapy, 1994, 8, 473-477.	2.6	2
276	Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension. Journal of Hypertension, 2000, 18, 963-969.	0.5	2
277	Renal artery stenosis: today's questions. Current Opinion in Pharmacology, 2006, 6, 197-201.	3.5	2
278	The influence of six cardiovascular polymorphisms on a first event of ischemic heart disease is modified by sex and age. Coronary Artery Disease, 2009, 20, 499-505.	0.7	2
279	Aldosterone–Renin Ratio and Side-Selective Renal Perfusion in Essential Hypertension. American Journal of Hypertension, 2016, 29, 1311-1316.	2.0	2
280	Do biomarkers add anything to clinical prediction of mortality in older medical emergency department patients?. European Journal of Internal Medicine, 2020, 81, 106-107.	2.2	2
281	The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. Cardiovascular Drugs and Therapy, 2023, 37, 283-289.	2.6	2
282	Can low-grade renal artery stenosis be considered as cause for renovascular hypertension?. Journal of Human Hypertension, 2022, 36, 420-422.	2.2	2
283	Renal Extraction of Atrial Natriuretic Peptide in Hypertensive Patients With or Without Renal Artery Stenosis. Hypertension, 1996, 27, 1254-1258.	2.7	2
284	Night shifts and hypertension. Journal of Clinical Hypertension, 2022, 24, 609-610.	2.0	2
285	Does nitric oxide synthesis really contribute to systemic blood pressure control?. Journal of Hypertension, 1995, 13, 709.	0.5	1
286	Effects of antihypertensive drugs on various aspects of renal function. Cardiovascular Drugs and Therapy, 1997, 10, 803-808.	2.6	1
287	Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?—Reply. Archives of Internal Medicine, 2005, 165, 1312.	3.8	1
288	A116C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension. American Journal of Gastroenterology, 2005, 100, 2601-2602.	0.4	1

#	Article	IF	CITATIONS
289	The trained observer better predicts daytime ambulatory blood pressure measurement diastolic blood pressure in hypertensive patients than does an automated (Omron)device. Blood Pressure Monitoring, 2007, 12, 57-59.	0.8	1
290	The impact of the journal and its impact on the journal. European Journal of Internal Medicine, 2007, 18, 171-172.	2.2	1
291	Variable hypertension and latent diabetes: two of a kind?. Journal of Hypertension, 2009, 27, 1536-1537.	0.5	1
292	ASTRALogy: Unrealistic Expectations?. Current Hypertension Reports, 2010, 12, 143-145.	3.5	1
293	Towards more uniform conflict disclosures: the updated ICMJE conflict of interest reporting form. Medical Journal of Australia, 2010, 193, 7-8.	1.7	1
294	Nycthemeral Relationship between Renal Function and Sodium Homeostasis. Current Hypertension Reports, 2011, 13, 136-141.	3.5	1
295	Resistance to antihypertensive treatment. Journal of Hypertension, 2011, 29, 1861-1862.	0.5	1
296	Clinical end points in baroreflex activation therapy: what do we need to know?. Expert Review of Cardiovascular Therapy, 2013, 11, 683-688.	1.5	1
297	Unilateral baroreceptor activation therapy: the beauty of asymmetry. Expert Review of Cardiovascular Therapy, 2015, 13, 739-741.	1.5	1
298	Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion. Journal of Hypertension, 2016, 34, 1607-1614.	0.5	1
299	Aldosterone Is Not Associated With Metabolic and Microvascular Insulin Sensitivity in Abdominally Obese Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 759-767.	3.6	1
300	Home and office blood pressure: time to look at the individual patient. Hypertension Research, 2021, 44, 473-474.	2.7	1
301	SHORT-TERM RENAL HEMODYNAMIC CHANGES IN PATIENTS RECEIVING A RENAL ALLOGRAFT. Transplantation, 1994, 57, 1661-1663.	1.0	1
302	Does nitric oxide synthesis really contribute to systemic blood pressure control? ??? Reply. Journal of Hypertension, 1995, 13, 1221.	0.5	0
303	Circulating adrenaline is not involved in the circadian blood pressure profile. Journal of Hypertension, 1995, 13, 1585???1588.	0.5	0
304	On sleep and death: cardiovascular risk of the obstructive sleep apnea syndrome. Netherlands Journal of Medicine, 1999, 54, 188-190.	0.5	0
305	Ambulatory and self-monitoring of blood pressure: Coming of age. Current Hypertension Reports, 2002, 4, 173-175.	3.5	0
306	Antihypertensive treatment and the kidney. Cardiovascular Drugs and Therapy, 2002, 16, 483-484.	2.6	0

#	Article	IF	CITATIONS
307	Renal protection from glomerular fibrosis. Journal of Hypertension, 2003, 21, 687-689.	O.5	Ο
308	Clonidine—Revisited, Relived or Time for Further Investigations?. Cardiovascular Drugs and Therapy, 2005, 19, 5-6.	2.6	0
309	Editorial developments at the journal. European Journal of Internal Medicine, 2007, 18, 355-356.	2.2	0
310	Response to Brain Microbleeds, Amyloid Plaques, Intellectual Deterioration, and Arterial Stiffness. Hypertension, 2008, 51, .	2.7	0
311	Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe Trial. International Journal of Cardiology, 2009, 137, S39-S40.	1.7	0
312	Does nocturnal blood pressure impair renal function?. Journal of Hypertension, 2010, 28, 430-431.	0.5	0
313	Treatment of Renal Artery Stenosis—Reply. JAMA - Journal of the American Medical Association, 2013, 309, 2321.	7.4	0
314	Review: Targeting SBP lowering to <Â140 mm Hg reduces MACE more than targeting SBP to >Â140 in hypertensive patients ≥Â65 y. Annals of Internal Medicine, 2017, 166, JC55.	3.9	0
315	Who removes the mask of hypertension?. Hypertension Research, 2017, 40, 964-965.	2.7	0
316	Reply. Journal of Hypertension, 2017, 35, 1721-1722.	0.5	0
317	Reply. Journal of Hypertension, 2017, 35, 2327-2328.	0.5	0
318	Author response: Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies. Neurology, 2017, 89, 2214-2215.	1.1	0
319	Disease or adaptation: another look at the practice of medicine. Postgraduate Medicine, 2018, 130, 239-243.	2.0	0
320	A sluice to normotension?. Journal of Hypertension, 2018, 36, 2314-2315.	0.5	0
321	Adenosine induces renal vasodilation in primary hypertensive patients. Journal of Hypertension, 1991, 9, S216.	0.5	0
322	Atherosclerotic Renovascular Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 21-32.	0.1	0
323	Value of biomarkers in predicting mortality in older medical emergency department patients: a Dutch prospective study. BMJ Open, 2021, 11, e042989.	1.9	0